ADARx Pharmaceuticals, Inc.
NASDAQ:ADRXBiotechnology
+$0.13 today
- Market cap
- $1.42B
- Beta
- 0.00
Volume 0.65M
Average 1.06M
ADRX Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Financing Cash Flow history
Currency unavailable · from the cash flow
No Financing Cash Flow data reported for this period type.
Financing Cash Flow vs competitors
How ADRX compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $489.54M USD | +101.0% | +93.7% | 681.8% | |
| LTM Mar 2026 | $180.34M USD | +37.9% | +28.0% | 562.2% | |
| LTM Mar 2026 | $145.91M USD | +227.5% | -5.8% | 3616.9% | |
| LTM Mar 2026 | $106.87M USD | -1.1% | — | — | |
| FY2025 | $42.57M USD | — | — | 228.7% | |
| LTM Mar 2026 | $1.8M USD | -109.8% | — | 4.0% | |
| LTM Mar 2026 | €1.63M EUR | -102.3% | -61.5% | 12.2% | |
| LTM Mar 2026 | $446K USD | -99.2% | -49.5% | 0.6% | |
| LTM Mar 2026 | $911.01 USD | — | -93.4% | 0.1% | |
ADRXADARx Pharmaceuticals, Inc. | — | — | — | — | — |
| Peer median (excluding ADRX) | — | -1.1% | -27.7% | 120.4% | |
Competitors are the stored peer set for ADRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
ADARx Pharmaceuticals, Inc.
NASDAQ:ADRX
Intrinsic Alpha fair value
Locked
Current Price
$12.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.